Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use
Epilepsy, Chronic Pain
About this trial
This is an interventional treatment trial for Epilepsy focused on measuring Gabapentin, OCT2, OCTN1, Pharmacogenetics, Pharmacokinetics, Polymorphisms
Eligibility Criteria
Inclusion Criteria:
- Patients with 18 years old or older, both gender.
- Patients undergoing chronic use of gabapentin (at least one week).
Exclusion Criteria:
- Pregnant and lactating patients.
- Patients who were in use of OCT2 and OCTN1 inhibitors.
- Patients who disagree to continue the study.
Sites / Locations
- Universidade Estadual Paulista Júlio de Mesquita Filho
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Homozygous for the wild type allele
Homo- or heterozygous for rare alleles
Patients with 18 years old or older with epilepsy, neuropathic pain or any chronic pain undergoing chronic treatment with gabapentin are being recruited. Sparse blood sampling are being collected up to 4 h after administration of the drug for pharmacokinetic study. Urine sampling are being collected during the dosing interval, only in patients hospitalized at the Hospital Estadual de Américo Brasiliense (HEAB). Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G>T and SLC22A4 c.1507C>T polymorphisms.
Patients with 18 years old or older with epilepsy, neuropathic pain or any chronic pain undergoing chronic treatment with gabapentin are being recruited. Sparse blood sampling are being collected up to 4 h after administration of the drug for pharmacokinetic study. Urine sampling are being collected during the dosing interval, only in patients hospitalized at the Hospital Estadual de Américo Brasiliense (HEAB). Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G>T and SLC22A4 c.1507C>T polymorphisms.